CMBA
MGNX icon

C.M. Bidwell & Associates’s MacroGenics MGNX Stock Holding History

C.M. Bidwell & Associates’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-8,195
Closed -$261K – 602
2021
Q1 		$261K Buy
8,195
+1,500
+22% +$36.4K 0.19% 82
2020
Q4 		$153K Buy
+6,695
New +$154K 0.13% 171

Other funds holding MGNX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

C.M. Bidwell & Associates's MGNX Position: Q2 2021 in Review

C.M. Bidwell & Associates sold out of MacroGenics (MGNX) in Q2 2021, closing a stake of 8,195 shares — an estimated $261K sold.

C.M. Bidwell & Associates first reported a position in MGNX in Q4 2020 and held it in 2 quarters. The position peaked at $261K in Q1 2021. 149 funds tracked by Wall St. Rank hold MGNX as of Q2 2021.

  • C.M. Bidwell & Associates reported no remaining MacroGenics position as of Q2 2021 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 8,195 MacroGenics shares in Q2 2021, an estimated $261K.
  • C.M. Bidwell & Associates first reported a position in MacroGenics in Q4 2020 and held it in 2 quarters.
  • C.M. Bidwell & Associates's MacroGenics position peaked at $261K in Q1 2021.
  • 149 funds tracked by Wall St. Rank held MacroGenics as of Q2 2021.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2021, filed 13 Aug 2021.